ASCO 2023 | Comparing IO/TKI and TKI monotherapy for kidney cancer

David A. Braun, MD, PhD, Yale School of Medicine, New Haven, CT, discusses the treatment options for patients who have progressive kidney cancer. International metastatic renal cell carcinoma database consortium (IMDC) favorable risk patients usually respond well to various treatments. Recently, long-term survival benefits have shown no difference between immuno-oncology/tyrosine kinase inhibitors (IO/TKIs) versus TKI monotherapy. In finding treatment solutions for patients who experience progression on anti-PD1 therapy, rechallenge would likely not be beneficial. Current trials are focused on incremental improvements. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.